Secukinumab (Scapho®) AI Pen 

Adult plaque psoriasis  

Scapho is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. 

Pediatric plaque psoriasis Treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. 

Psoriatic arthritis  

Scapho is indicated for the treatment of active psoriatic arthritis in adult patients, alone or in combination with methotrexate (MTX), when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. 

Axial spondyloarthritis (axSpA) with or without radiographic damage 

Ankylosing spondylitis (AS) / axSpA with radiographic damage  

Scapho is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. 

Non-radiographic axial spondyloarthritis (nr-axSpA) / axSpA without radiographic damage 

Scapho is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation. 

To know more, click the Prescribing Info below.  

Prescribing Information (AI Pen and Vial)